NCT02560779View on ClinicalTrials.gov

Trial of TRC105 and Sorafenib in Patients With HCC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Carotuximab (TRC105)

Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.

DRUG

Sorafenib

400 mg of sorafenib will be given twice daily.

Trial Locations (3)

44106

University Hospitals, Cleveland

35294-3300

University of Alabama, Birmingham

77030-4009

MD Anderson, Houston

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT02560779 - Trial of TRC105 and Sorafenib in Patients With HCC | Biotech Hunter | Biotech Hunter